Zejula® (niraparib) – Indication update
November 11, 2022 - GSK announced an update that at the request of the FDA, it will restrict the second-line maintenance indication for Zejula (niraparib) to only the patient population with deleterious or suspected deleterious germline BRCA mutations (gBRCAmut).
Top